The cytokine storm and COVID‐19

B Hu, S Huang, L Yin - Journal of medical virology, 2021 - Wiley Online Library
Abstract Coronavirus disease 2019 (COVID‐19), which began in Wuhan, China, in
December 2019, has caused a large global pandemic and poses a serious threat to public …

Treatment for COVID-19: An overview

C Stasi, S Fallani, F Voller, C Silvestri - European journal of pharmacology, 2020 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19) is an infectious disease caused by
coronavirus-2 (SARS-CoV-2) that causes a severe acute respiratory syndrome, a …

Potently neutralizing and protective human antibodies against SARS-CoV-2

SJ Zost, P Gilchuk, JB Case, E Binshtein, RE Chen… - Nature, 2020 - nature.com
The ongoing pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major threat to global health …

Delayed production of neutralizing antibodies correlates with fatal COVID-19

C Lucas, J Klein, ME Sundaram, F Liu, P Wong… - Nature medicine, 2021 - nature.com
Recent studies have provided insights into innate and adaptive immune dynamics in
coronavirus disease 2019 (COVID-19). However, the exact features of antibody responses …

Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review

I Monsef, C Doree, EM Wood… - Cochrane Database …, 2020 - cochranelibrary.com
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …

Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad

S Ahmed, O Zimba, AY Gasparyan - Clinical Rheumatology, 2020 - Springer
The pathogenesis of Coronavirus disease 2019 (COVID-19) is gradually being
comprehended. A high number of thrombotic episodes are reported, along with the mortality …

Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy

M Helleberg, CU Niemann, KS Moestrup… - The Journal of …, 2020 - academic.oup.com
The antiviral drug remdesivir has been shown clinically effective for treatment of COVID-19.
We here demonstrate suppressive but not curative effect of remdesivir in an …

Worse progression of COVID‐19 in men: is testosterone a key factor?

VA Giagulli, E Guastamacchia, T Magrone, E Jirillo… - …, 2021 - Wiley Online Library
Background The novel severe acute respiratory syndrome coronavirus (SARS‐CoV‐2)
disease 2019 (COVID‐19) seems to have a worse clinical course among infected men …

[HTML][HTML] Predictors and outcomes of healthcare-associated infections in COVID-19 patients

G Kumar, A Adams, M Hererra, ER Rojas… - International Journal of …, 2021 - Elsevier
Introduction Healthcare-associated infections (HAI) after viral illnesses are important
sources of morbidity and mortality. This has not been extensively studied in hospitalized …

[HTML][HTML] A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19

K Sharun, R Tiwari, MI Yatoo, S Natesan, D Megawati… - Narra J, 2022 - ncbi.nlm.nih.gov
The emergence of coronavirus disease 2019 (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected many countries throughout …